by Paige Minemyer | Nov 1, 2018 12:01am
Public health policies
targeting diabetes could use a serious refresher as the disease rate
skyrockets, according to a new white paper.
The number of patients
with Type 2 diabetes has reached nearly 10% of the adult U.S.
population, with an additional 1.5 million people diagnosed between 2016 and
2017, according to the report from the Keckley Group.
If 20% of the 30 million
people with Type 2 diabetes reduced their HbA1c levels—a key indicator for the
disease—by just 1%, it would save at least $10 billion each year in healthcare
costs.
Extrapolated to the 84
million people who are prediabetic, the savings could grow significantly,
according to the report. Chronic diseases, of which Type 2 diabetes is a prime
example, account for 84% of healthcare costs.
Paul Keckley,
president of the organization, author of the study and well-known industry
expert, told FierceHealthcare said managing conditions like diabetes
can fall by the wayside as that type of care management isn’t exactly lucrative
for providers.
“This is probably a
reflection of neglect on the part of the system,” he said, “and now it’s come
home to roost.”
Policymakers, working
with providers and public health agencies, should take two steps immediately,
according to the report:
- Update dietary guidelines to
reflect that a one-size-fits-all approach doesn’t work in this patient
population. Any number of socioeconomic and lifestyle factors can impact
how useful these guidelines are to a patient at present, according to the
report.
- Launch a public outreach
campaign that makes patients more aware of nutritional health therapies,
such as low carbohydrate options, that could benefit them, even if
they’re not diabetic.
Providers should also
consider updating the screenings they use for Type 2 diabetes and include
nutritional therapies in their training, the report suggests. New, value-based
care models also need to include and cover nutrition.
“Let’s prescribe
diets the way we prescribe drugs, and we’ll lessen the need for those
drugs,” Keckley said.
Keckley said that
big-name payers are also catching on to the need for better diabetes
care management and are investing in programs that care for patients
more holistically.
Payers are
well-positioned to lead this charge, he said, because they have a wealth of
data available and are already in the business of managing and overseeing other
elements of care, such as medication adherence and spending.
That investment has
to extend to public payers as well to be truly effective, he said.
“Big public payers have
to be in the business of managing lifestyle and choices, not just make
sure you’ve got beds and pills,” Keckley said.
No comments:
Post a Comment